ArticleBreast cancer research and treatment2014
Ex vivo Evans blue assessment of the blood brain barrier in three breast cancer brain metastasis models.
Article in Breast cancer research and treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Evaluation the Effect of Sonodynamic Therapy with 5-Aminolevulinic Acid and Sodium Fluorescein by Preclinical Animal Study.Cancers · 2024Article
- Selective and brain-penetrant ACSS2 inhibitors target breast cancer brain metastatic cells.Frontiers in pharmacology · 2024Article
- Fn14-Directed DART Nanoparticles Selectively Target Neoplastic Cells in Preclinical Models of Triple-Negative Breast Cancer Brain Metastasis.Molecular pharmaceutics · 2023Article
- Development and characterization of a rat brain metastatic tumor model by multiparametric magnetic resonance imaging and histomorphology.Clinical & experimental metastasis · 2022Article
- Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy.Science advances · 2022Article
- PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8Clinical & experimental metastasis · 2022Article
- Systemic treatments for breast cancer brain metastasis.Frontiers in oncology · 2022Review
- Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer.Science advances · 2020Article
- How to Make Anticancer Drugs Cross the Blood-Brain Barrier to Treat Brain Metastases.International journal of molecular sciences · 2019Review
- Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.Neuro-oncology · 2019Article
- Long-term characterization of activated microglia/macrophages facilitating the development of experimental brain metastasis through intravital microscopic imaging.Journal of neuroinflammation · 2019Article
- The Role and Mechanism of Borneol to Open the Blood-Brain Barrier.Integrative cancer therapies · 2018Article
- Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases.Nature communications · 2018Article
- Evans Blue Dye: A Revisit of Its Applications in Biomedicine.Contrast media & molecular imaging · 2018Review
- Maintaining unperturbed cerebral blood flow is key in the study of brain metastasis and its interactions with stress and inflammatory responses.Brain, behavior, and immunity · 2017Article
- Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice.Acta pharmacologica Sinica · 2017Article
- Therapeutics for Brain Metastases, v3.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Advances in decoding breast cancer brain metastasis.Cancer metastasis reviews · 2016Review
- Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The limited entry of anticancer drugs into the central nervous system represents a special therapeutic challenge for patients with brain metastases and is primarily due to the blood brain barrier (BBB). Albumin-bound Evans blue (EB) dye is too large to cross the BBB but can grossly stain tissue blue when the BBB is disrupted. The course of tumor development and the integrity of the BBB were studied in three preclinical breast cancer brain metastasis (BCBM) models. A luciferase-transduced braintropic clone of MDA-231 cell line was used. Nude mice were subjected to stereotactic intracerebral inoculation, mammary fat pad-derived tumor fragment implantation, or carotid artery injections. EB was injected 30 min prior to euthanasia at various timepoints for each of the BCBM model animals. Serial bioluminescent imaging demonstrated exponential tumor growth in all models. Carotid BCBM appeared as diffuse multifocal cell clusters. EB aided the localization of metastases ex vivo. Tumor implants stained blue at 7 days whereas gross staining was not evident until day 14 in the stereotactic model and day 28 for the carotid model. EB assessment of the integrity of the BBB provides useful information relevant to drug testing in preclinical BCBM models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.